Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy

Tanishima, Hiroyuki; Tominaga, Toshiji; Kimura, Minami; Maeda, Tsunehiro; Shirai, Yasutsugu; Horiuchi, Tetsuya

doi:10.1007/s00520-016-3514-6

Cited by 26 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, actions for managing OXA-NTS are limited [23][24][25] and patients often need to learn how to manage the side effects on their own in daily life 5,26 . A study shows that the occurrence of hyperacute OXA-NTS can be a predictor of chronic neurotoxicity, which highlights the importance of careful monitoring 27 A strength of this study is the real-time assessments, which seem to be an accurate and valid method for follow-up of PROs. There may be an advantage that the patients in this study were observed and dose-adjusted to a greater extent, which resulted in fewer experienced and reported side effects.…”

Section: Discussionmentioning

confidence: 89%

Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

et al. 2018

View full text Add to dashboard Cite

Background: Oxaliplatin (OXA) is frequently used in the treatment of patients with colorectal cancer (CRC) and OXA-induced neurotoxic side effects is common. Real time patient-reported neurotoxic side effects and impact on the patient's daily activities, are sparse in existing studies. Objective: This study aimed to identify and assess patient-reported OXA-induced neurotoxic side effects and their impact on the patient's daily activities, during and after chemotherapy. Methods: In a multicentre prospective longitudinal study, 46 chemo naïve patients with CRC treated with postoperative adjuvant OXA-based chemotherapy were monitored during treatment and at 3-, 6-, 9-and 12-month follow-ups. Patients were recruited from September 2013 to June 2016. In total, 370 OANQ (Oxaliplatin-Associated Neurotoxicity Questionnaire) responses were available for analysis. A mobile phone-based system was used to receive real time assessments. Results: All patients reported neurotoxic side effects and impact on daily activities during treatment. The side effects changed in character and body location over time, and had an impact on the daily activities. Conclusions: The high prevalence of OXA-induced neurotoxic side effects significantly interfered with the patients' daily activities. We found significant differences between baseline data and follow-up time points for neurotoxicity, and the patients had not returned to baseline after one year.

show abstract

Section: Discussionmentioning

confidence: 89%

Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The oxaliplatin acute neurotoxicity is characterized by transient paresthesia, dysesthesia, and muscle cramps induced by cold exposure, a phenomenon often called cold allodynia or hyperalgesia that typically resolves before the next oxaliplatin cycle . Symptoms reported by patients include paresthesia and/or dysesthesia in the perioral, pharyngeal, and laryngeal regions, as well as in the distal limbs triggered and exacerbated by cold (especially when drinking beverages), abnormal breathing and swallowing, muscle spasms, or cramps among other uncommon symptoms related to the acute oxaliplatin hyperexcitability syndrome . Acute peripheral neurotoxicity to oxaliplatin, documented either by clinical symptoms or quantitative sensory testing, has been demonstrated to be associated with the development of chronic peripheral neuropathy.…”

Section: Clinical Aspects Of Pipnmentioning

confidence: 99%

“…Acute peripheral neurotoxicity to oxaliplatin, documented either by clinical symptoms or quantitative sensory testing, has been demonstrated to be associated with the development of chronic peripheral neuropathy. This observation has the potential of making the acute neurotoxicity a predictor for selecting patients who may benefit from neuroprotective strategies …”

Section: Clinical Aspects Of Pipnmentioning

confidence: 99%

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

Staff

Cavaletti

Islam

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Platinum-induced peripheral neurotoxicity (PIPN) is a common side effect of platinum-based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin being more neurotoxic. PIPN includes acute neurotoxicity restricted to oxaliplatin, and chronic non-length-dependent sensory neuronopathy with positive and negative sensory symptoms and neuropathic pain in both upper and lower limbs.Chronic sensory axonal neuropathy manifesting as stocking-and-glove distribution is also frequent. Worsening of neuropathic symptoms after completing the last chemotherapy course may occur. Motor and autonomic involvement is uncommon. Ototoxicity is frequent in children and more commonly to cisplatin. Platinum-based compounds result in more prolonged neuropathic symptoms in comparison to other chemotherapy agents. Patient reported outcomes questionnaires, clinical evaluation and instrumental tools offer complementary information in PIPN. Electrodiagnostic features include diffusely reduced/abolished sensory action potentials, in keeping with a sensory neuronopathy. PIPN is dependent on cumulative dose but there is a large variability in its occurrence. The search for additional risk factors for PIPN has thus far yielded no consistent findings. There are currently no neuroprotective strategies to reduce the risk of PIPN, and symptomatic treatment is limited to duloxetine that was found effective in a single phase III intervention study. This review critically examines the pathogenesis, incidence, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of PIPN.

show abstract

“…Though risk estimates vary considerably, incidence of severe (Common Terminology Criteria for Adverse Events (CTCAE) Grade 3+) chronic neuropathy may be up to 50% depending on treatment duration (15). Hyper-acute peripheral neuropathy, defined as upper extremity and laryngopharyngeal dysesthesia within 24 hours of the first cycle of chemotherapy, may be one clinical predictor of persistent OIN (16). Other associated factors include duration and intensity of symptoms after six treatment cycles, body surface area (BSA), and concomitant use of bevacizumab, while factors such as age, sex, performance status, comorbid diabetes, and prior treatment history do not seem to be associated (17,18).…”

mentioning

confidence: 99%

Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

et al. 2020

View full text Add to dashboard Cite

Background/Aim: Oxaliplatin-induced neurotoxicity (OIN) can be severe and dose-limiting with clinically significant symptoms that persist for years. Few published reports have described postoperative exacerbation of OIN and more longitudinal data are needed to better characterize the phenomenon. Patients and Methods: We identified 13 patients diagnosed with colon (n=7), rectal (n=4) or pancreatic (n=2) cancer who experienced postoperative OIN exacerbation at our medical center. Charts were reviewed for demographic and clinical data regarding OIN. Results: OIN exacerbation was documented 0.5-7.0 months after the first surgery following oxaliplatin exposure, with a median duration of 10.6 months (range=1.4-86.1 months). OIN exacerbation persisted in 3/13 patients at last follow-up, and improved to pre-operative levels in 6/13 patients (with complete resolution in 4/13) within a median of 3.6 months from initial exacerbation. Conclusion: Given the widespread use of oxaliplatin in neoadjuvant and first-line treatment for gastrointestinal cancers, further study is warranted to prospectively and systematically define risks for postoperative OIN exacerbation.

show abstract

Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy

Abstract: HAPN was found to be a predictor of oxaliplatin-induced PPN.

Cited by 26 publications

References 33 publications

Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

Contact Info

Product

Resources

About